CoChat

Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes

Davies, M. J., Kela, R., Khunti, K. · 2011 · Diabetes, Obesity and Metabolism
Cited by 66

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes is characterized by a progressive decline in glycaemic control. Many standard diabetes treatments, however, fail to achieve or maintain glycaemic control, and are often associated with an increased risk of hypoglycaemia and weight gain. Recently developed incretin‐based therapies are a promising addition to the current armamentarium of diabetes treatments. Two types of incretin‐based therapies are currently available: glucagon‐like peptide (GLP)‐1 receptor agonists (liraglutide and exenatide) and dipeptidyl peptidase‐4 inhibitors (sitaglipin, vildagliptin and saxagliptin). This review aims to summarize the key efficacy and safety data of liraglutide, a once‐daily human GLP‐1 analogue. Extensive phase III clinical trials have shown liraglutide to improve glycaemic control with additional benefits on body weight, blood pressure and β ‐cell function. Liraglutide is also generally well tolerated with a low risk of hypoglycaemia. Liraglutide has recently been approved for marketing in Europe, Japan and the USA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2010.01330.x

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 66

Metadata

Authors
Davies, M. J., Kela, R., & Khunti, K.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-01-24
Volume
13
Issue
3
Pages
207-220
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1969181381
Cited by
66
References
26
FWCI
4.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01330.x
The paper
Davies, M. J., Kela, R., & Khunti, K. (2011). Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01330.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.